Skip to main content

Table 1 Patients’ characteristics

From: Evaluation of patients’ expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index – the benefica study

 

N = 3089

Age (years)

38.8 ± 13.7

Males

1481 (48.2%)

Active smokers

642 (20.8%)

Passive smokers

507 (16.4%)

Occupational exposure to allergens

416 (14.1%)

Duration of allergic rhinitis (years)

14.5 ± 11.0

Perennial rhinorrhea

668 (22.3%)

ARIA classification of rhinitis

 

  Mild and intermittent

58 (1.9%)

  Moderate and intermittent

314 (10.3%)

  Mild and persistent

216 (7.1%)

  Moderate and persistent

2463 (80.7%)

Concomitant diseases

 

  Rhinosinusitis

418 (13.5%)

  Sero-mucous otitis

43 (1.4%)

  Nose or sinus polyps

170 (5.5%)

  ENT disease*

588 (19.0%)

  Asthma

565 (18.3%)

  Atopic dermatitis

366 (11.9%)

  1. Results are expressed as mean ± SD for continuous variables and as a number (percentage) for categorical variables; *ENT disease includes rhinosinusitis, serous otitis media, and nose or sinus polyps.